3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
5
Urinary Bladder Neoplasms
4
Melanoma
4
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Sarcoma
2
Ovarian Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Merkel Cell
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Plasma Cell
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, T-Cell, Cutaneous
1
Lung Neoplasms
1
Kidney Neoplasms
1
Chondrosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Adenocarcinoma
1
Interventions
pembrolizumab
31
Nivolumab
12
Cyclophosphamide
10
fludarabine
9
aldesleukin
8
atezolizumab
7
durvalumab
6
Magnetic Resonance Spectroscopy
6
Trastuzumab
5
Specimen Handling
5
Paclitaxel
5
Ipilimumab
5
Docetaxel
5
Biopsy
5
fludarabine phosphate
4
Radiotherapy
4
Interleukin-2
4
Gene Expression Profiling
4
Carboplatin
4
tisotumab vedotin
3
cemiplimab
3
aflibercept
3
Polymerase Chain Reaction
3
Immunoglobulin G
3
Early Intervention, Educational
3
Cisplatin
3
Bevacizumab
3
tremelimumab
2
tislelizumab
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
poly ICLC
×
Genitourinary
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled